1. Supplementary Figure 1 Lapatinib nM mM pEGFR MDA-MB231 EGFR pEGFRC 50
100
250
500 1
2.5 5
pEGFR
MDA-MB231
EGFR
pEGFR
HS578T
EGFR
pEGFR
HBL100
EGFR
Dasatinib nM mM C 10 50
100
250
500 1
1.5
pPDGFRb
HS578T
PDGFRb
Sorafenib nM mM C 10 25 50
100
250
500 1
2.5
pErk1/2
MDA-MB231
Erk2
Selumetinib nM mM
BEZ235, nM C
100
250
500 1
2.5 5 10 C 25 50
100
250
pErk1/2
pAkt
MDA-MB231
HS578T
Erk2
Akt
Supplementary Figure 1. Action of the different kinase inhibitors on the phosphorylation status of their targets or readout proteins. The cell lines were treated with the indicated concentrations of the drugs for 4 hours, and then lysed. Cell lysates were subjected to immunoprecipitation with antibodies to EGFR or PDGFRb, and the total amount of receptors or their tyrosine phosphorylation analysed by Western blot with anti-receptor or anti-PY antibodies, respectively. Detection of the phosphorylated forms of Erk1/2 and Akt was performed by Western blot of cell lysates.
Supplementary Figure 1